Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.
Adult
Aged
Aged, 80 and over
Alleles
Antineoplastic Agents
/ therapeutic use
Female
Gene Frequency
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/ drug therapy
Leukemia, Neutrophilic, Chronic
/ drug therapy
Male
Middle Aged
Nitriles
Protein Kinase Inhibitors
/ adverse effects
Pyrazoles
/ adverse effects
Pyrimidines
Receptors, Colony-Stimulating Factor
/ genetics
Survival Rate
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333
Informations de publication
Date de publication:
01 04 2020
01 04 2020
Historique:
pubmed:
28
12
2019
medline:
26
1
2021
entrez:
28
12
2019
Statut:
ppublish
Résumé
Colony-stimulating factor-3 receptor ( We conducted a phase II study of ruxolitinib in 44 patients (21 CNL and 23 aCML). The primary end point was overall hematologic response rate (ORR) by the end of 6 continuous 28-day cycles for the first 25 patients enrolled. We considered a response as either partial (PR) or complete response (CR). We expanded accrual to 44 patients to increase our ability to evaluate secondary end points, including grade ≥ 3 adverse events, spleen volume, symptom assessment, genetic correlates of response, and 2-year survival. ORR was 32% for the first 25 enrolled patients (8 PR [7 CNL and 1 aCML]). In the larger cohort of 44 patients, 35% had a response (11 PR [9 CNL and 2 aCML] and 4 CR [CNL]), and 50% had oncogenic Ruxolitinib was well tolerated and demonstrated an estimated response rate of 32%. Patients with a diagnosis of CNL and/or harboring
Identifiants
pubmed: 31880950
doi: 10.1200/JCO.19.00895
pmc: PMC7106977
doi:
Substances chimiques
Antineoplastic Agents
0
CSF3R protein, human
0
Nitriles
0
Protein Kinase Inhibitors
0
Pyrazoles
0
Pyrimidines
0
Receptors, Colony-Stimulating Factor
0
ruxolitinib
82S8X8XX8H
Banques de données
ClinicalTrials.gov
['NCT02092324']
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1006-1018Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA224019
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA183974
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA217862
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA069533
Pays : United States
Références
Blood. 2013 Dec 12;122(25):4047-53
pubmed: 24174625
N Engl J Med. 2012 Mar 1;366(9):799-807
pubmed: 22375971
Blood Cancer J. 2018 Feb 15;8(2):21
pubmed: 29449543
Leukemia. 2017 Aug;31(8):1770-1778
pubmed: 28031554
Haematologica. 2017 May;102(5):e207-e209
pubmed: 28209656
Nat Genet. 2013 Aug;45(8):942-6
pubmed: 23832012
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Blood. 2008 Jan 1;111(1):86-93
pubmed: 17893227
Mol Cancer. 2018 Feb 19;17(1):40
pubmed: 29455651
Bone Marrow Transplant. 2004 Dec;34(12):1047-50
pubmed: 15516946
Saudi Med J. 2015 Aug;36(8):967-72
pubmed: 26219448
Lancet Oncol. 2009 Mar;10(3):223-32
pubmed: 19230772
N Engl J Med. 2013 May 9;368(19):1781-90
pubmed: 23656643
Blood. 2015 Mar 19;125(12):1857-65
pubmed: 25624319
Blood. 1998 Jul 1;92(1):32-9
pubmed: 9639496
Blood. 2013 Nov 21;122(22):3628-31
pubmed: 24081659
Blood. 2009 Mar 26;113(13):2895-901
pubmed: 18988864
Haematologica. 2015 Sep;100(9):1139-45
pubmed: 26069290
Haematologica. 2017 Jun;102(6):e238-e240
pubmed: 28302714
Pediatr Blood Cancer. 2016 Jan;63(1):156-9
pubmed: 26274939
Leukemia. 2013 Sep;27(9):1870-3
pubmed: 23604229
Haematologica. 2006 Nov;91(11):1566-8
pubmed: 17043019
Curr Hematol Malig Rep. 2017 Oct;12(5):432-441
pubmed: 28983816
Blood Res. 2013 Sep;48(3):178-84
pubmed: 24086937
PLoS One. 2017 Feb 3;12(2):e0171608
pubmed: 28158286
Leukemia. 2013 Oct;27(10):2072-5
pubmed: 23648668
Blood. 2004 Jan 15;103(2):571-9
pubmed: 14512302
Blood. 2011 Jul 14;118(2):401-8
pubmed: 21536863
Clin Cancer Res. 2016 Feb 1;22(3):757-64
pubmed: 26475333
Leukemia. 2005 Feb;19(2):313-7
pubmed: 15549147
Leukemia. 2013 Oct;27(10):2100-2
pubmed: 23558523
Leuk Res Rep. 2014 Aug 01;3(2):67-9
pubmed: 25180155
Eur J Haematol. 2014 Mar;92(3):189-94
pubmed: 24164563
J Biol Chem. 2014 Feb 28;289(9):5820-7
pubmed: 24403076
Cureus. 2015 Dec 17;7(12):e414
pubmed: 26870618
Am J Hematol. 2016 Mar;91(3):341-9
pubmed: 26700908
Blood. 2014 Apr 24;123(17):2645-51
pubmed: 24627528
Leukemia. 2013 Jun;27(6):1401-3
pubmed: 23443343
Blood. 2007 Nov 15;110(10):3540-6
pubmed: 17715389